Aptus Capital Advisors, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.

Quarter-by-quarter ownership
Aptus Capital Advisors, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2022$46,000
+64.3%
10,360
+1.5%
0.00%0.0%
Q2 2022$28,000
-33.3%
10,210
-18.3%
0.00%0.0%
Q1 2022$42,000
-16.0%
12,5000.0%0.00%
-50.0%
Q4 2021$50,000
-5.7%
12,500
-21.9%
0.00%
+100.0%
Q3 2021$53,000
-24.3%
16,000
-12.8%
0.00%
-50.0%
Q2 2021$70,000
+14.8%
18,350
+14.3%
0.00%0.0%
Q1 2021$61,000
-60.4%
16,050
-53.0%
0.00%
-71.4%
Q4 2020$154,00034,1500.01%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2020
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 241,500$1,093,0000.17%
OCCUDO QUANTITATIVE STRATEGIES LP 90,584$410,0000.13%
EPIQ PARTNERS, LLC 10,550$48,0000.03%
Phoenix Holdings Ltd. 173,683$799,0000.02%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 5,500$25,0000.02%
CFO4Life Group, LLC 12,003$54,0000.02%
HighPoint Advisor Group LLC 15,733$115,0000.01%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 357,761$1,619,0000.01%
Virtu Financial LLC 24,484$111,0000.01%
ETF MANAGERS GROUP, LLC 93,902$435,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders